Patricia Myers

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised Movable Ink, an artificial intelligence-powered personalized content platform, on its definitive agreement to be acquired by STG. The transaction is expected to close in July 2025.

Cooley advised SoftEye, a San Diego-based company developing specialized chips, cameras, software and algorithms for use in smart glasses, on its sale to TDK Corporation, a Tokyo-based global leader in advanced electronic solutions designed for a smarter, more connected world.

Cooley advised Medically Home, a provider of a hospital-at-home technology enablement model for health systems and physician groups to safely deliver emergency and hospital-level care at home, on its merger with DispatchHealth, a provider of high-acuity, in-home medical care for people experiencing serious health concerns.